<DOC>
	<DOCNO>NCT02069639</DOCNO>
	<brief_summary>Relapsed refractory Hodgkin 's lymphoma ( HL ) patient may experience long-term survival allogeneic transplant ( alloSCT ) , disease recurrence represent main cause treatment failure . PET ( positron-emission tomography ) -positive patient alloSCT dismal outcome . Serum TARC ( thymus activation-regulated chemokine ) produce Reed-Sternberg cell may marker disease . Our study aim assess whether TARC level alloSCT correlate disease status whether TARC monitoring could increase ability predict relapse .</brief_summary>
	<brief_title>TARC After alloSCT Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Hodgkin 's lymphoma patient underwent alloSCT Fondazione IRCCS Istituto Nazionale dei Tumori monitor PET TARC alloSCT 2009 Hodgkin 's lymphoma patient underwent alloSCT monitor PET or/and TARC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>